DrugPatentWatch Database Preview
Details for Patent: RE44874
» See Plans and Pricing
Which drugs does patent RE44874 protect, and when does it expire?
Patent RE44874 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.
This patent has fifty-three patent family members in thirty countries.
Summary for Patent: RE44874
| Title: | Phenethanolamine derivatives for treatment of respiratory diseases |
| Abstract: | The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases ##STR00001## |
| Inventor(s): | Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB) |
| Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
| Application Number: | 13/719,797 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Use; Process; Device; Delivery; |
Drugs Protected by US Patent RE44874
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-001 | May 10, 2013 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Glaxo Grp Ltd | BREO ELLIPTA | fluticasone furoate; vilanterol trifenatate | POWDER;INHALATION | 204275-002 | Apr 30, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-001 | Sep 18, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE44874
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0122201.7 | Sep 14, 2001 |
| United Kingdom | 0126997.6 | Nov 9, 2001 |
| PCT Information | |||
| PCT Filed | September 11, 2002 | PCT Application Number: | PCT/GB02/04140 |
| PCT Publication Date: | March 27, 2003 | PCT Publication Number: | WO03/024439 |
International Family Members for US Patent RE44874
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 036874 | Start Trial | |||
| Argentina | 091595 | Start Trial | |||
| Austria | 417606 | Start Trial | |||
| Australia | 2002326026 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
